Details of Disease

General Information of Disease (ID: DISUG64F)

• Disease Name: Lung large cell carcinoma
• Synonyms: LCLC; lung large cell carcinoma; large cell undifferentiated lung carcinoma; large cell lung carcinoma; large cell lung cancer; large cell carcinoma of the lung; large cell carcinoma of lung; anaplastic lung carcinoma
• Definition: A poorly differentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular or squamous differentiation. There is a male predilection.
• Disease Hierarchy:
  DISYMCOF: Large cell carcinoma
  DIS5Y6R9: Non-small-cell lung cancer
  DISUG64F: Lung large cell carcinoma
• Disease Identifiers:
  MONDO ID: MONDO_0003050
  UMLS CUI: C0345958
  MedGen ID: 91060
  HPO ID: HP:0030360
  SNOMED CT ID: 254629004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Bevacizumab	DMSD1UN	Approved	Monoclonal antibody	[1]
Carboplatin	DMG281S	Approved	Small molecular drug	[2]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[3]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
STK33	TTP34DQ	moderate	Biomarker	[4]

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
PTPRG	OT9N2WOF	Strong	Altered Expression	[5]

References

• [1] Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94.
• [2] Carboplatin FDA Label
• [3] Paclitaxel FDA Label
• [4] Correlation between STK33 and the pathology and prognosis of lung cancer.Oncol Lett. 2017 Oct;14(4):4800-4804. doi: 10.3892/ol.2017.6766. Epub 2017 Aug 17.
• [5] Germline polymorphisms and survival of lung adenocarcinoma patients: a genome-wide study in two European patient series.Int J Cancer. 2015 Mar 1;136(5):E262-71. doi: 10.1002/ijc.29195. Epub 2014 Sep 19.